<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04295031</url>
  </required_header>
  <id_info>
    <org_study_id>AMEMET Study</org_study_id>
    <nct_id>NCT04295031</nct_id>
  </id_info>
  <brief_title>Metformin in Older Adults With Type 2 Diabetes (AMEMET)</brief_title>
  <acronym>AMEMET</acronym>
  <official_title>AMEMET Study - Observational Multicentric Clinical Study: Metformin in Patients Over 65 Years With Type 2 Diabetes (DM2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Medici Endocrinologi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Medici Endocrinologi</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, observational, cross-sectional study in Italy. The aims are to evaluate the
      daily metformin prescribed dose and the impact of renal function and concomitant medication
      in diabetic patients over 65 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was commissioned by the Italian Association of Clinical Endocrinologists
      (Association of Medical Endocrinologists - AME) and approved by the Ethical Committee of
      Cuneo Hospital. The research was open to all specialists taking care of patients with
      diabetes in Italy.

      The primary endpoint was the evaluation of metformin dosage. Secondary endpoints were the
      relationship between the metformin dosage and the renal filtration rate and the relationship
      between the metformin dosage and the concomitant medication.

      An ad hoc form was developed and used to record all medical findings. The form was emailed to
      all participating centers who then emailed or faxed it back to the investigator's data
      manager. Data were checked for accuracy.

      The following data were required: age, gender, body weight and height, diabetes duration,
      type of metformin (classical/slow), daily dosage of metformin, reported side
      effects,concomitant medications.

      Serum creatinine and HbA1c levels obtained within the previous two months were also required.

      Each participating center recruited about 50 diabetic outpatients. Inclusion criteria were as
      follows: adult outpatients ≥ 65 years with T2 diabetes mellitus, using metformin for at least
      six months, usually assuming three daily meals, and capable of informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>metformin daily dose in diabetic outpatients type 2</measure>
    <time_frame>six months</time_frame>
    <description>relationship between metformin dose and filtration rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal filtration rate</measure>
    <time_frame>six months</time_frame>
    <description>relationship between metformin rate and concomitant medication</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>DM2 without renal disease</arm_group_label>
    <description>patients with type 2 diabetes with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM2 with renal impairment</arm_group_label>
    <description>patients with type 2 diabetes with impaired renal function</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All diabetic patients respecting eligibility criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult outpatients (≥65 years);

          -  T2 diabetes mellitus;

          -  Taking metformin for at least six months;

          -  assuming three daily meals;

          -  capable of informed consent.

        Exclusion Criteria:

          -  severe liver or renal failure (eGFR &lt;30 mL/min/1.73 m2);

          -  hospitalization for any cause in the last six month;

          -  glucocorticoid treatment in the last six month;

          -  oncologic treatment in the last six month;

          -  Ramadan in the last six months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Borretta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associazione Medici Endocrinologi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Martello</last_name>
    <phone>+39 0432 204050</phone>
    <email>segreteria@associazionemediciendocrinologi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giorgio Borretta, MD</last_name>
    <email>borretta.giorgio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AME - Associazione Medici Endocrinologi</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Martello</last_name>
      <phone>+39 0432 204050</phone>
      <email>segreteria@associazionemediciendocrinologi.it</email>
    </contact>
    <contact_backup>
      <last_name>Giorgio Borretta, MD</last_name>
      <email>borretta.giorgio@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, Hirsch IB, McDonnell ME, Molitch ME, Murad MH, Sinclair AJ. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574. doi: 10.1210/jc.2019-00198.</citation>
    <PMID>30903688</PMID>
  </results_reference>
  <results_reference>
    <citation>Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018 Dec;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5. Erratum in: Diabetologia. 2019 May;62(5):873.</citation>
    <PMID>30288571</PMID>
  </results_reference>
  <results_reference>
    <citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.</citation>
    <PMID>30742570</PMID>
  </results_reference>
  <results_reference>
    <citation>Schlender L, Martinez YV, Adeniji C, Reeves D, Faller B, Sommerauer C, Al Qur'an T, Woodham A, Kunnamo I, Sönnichsen A, Renom-Guiteras A. Efficacy and safety of metformin in the management of type 2 diabetes mellitus in older adults: a systematic review for the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2017 Oct 16;17(Suppl 1):227. doi: 10.1186/s12877-017-0574-5. Review.</citation>
    <PMID>29047344</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

